Stay updated on Pembrolizumab in Poor-Prognosis CUP Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Poor-Prognosis CUP Clinical Trial page.

Latest updates to the Pembrolizumab in Poor-Prognosis CUP Clinical Trial page
- CheckyesterdayChange DetectedRevision label updated from v3.6.4 to v3.6.5 on the page, indicating a subsequent software update to the ClinicalTrials.gov entry.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe additions expand and clarify the study's secondary and primary endpoints, including RECIST 1.1-based response definitions, duration of response, disease control, and the time frames for OS and PFS. They also specify the assessment of adverse events and the overall analytic time horizons used in the study.SummaryDifference2%

- Check37 days agoChange DetectedResults posted and completion details updated, with enrollment recorded as 33. A PDF of the Study Protocol and Statistical Analysis Plan has been added under Study Documents.SummaryDifference3%

- Check44 days agoChange DetectedRevision tag on the page updated from v3.6.0 to v3.6.3, indicating a backend update rather than changes to the study data.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page gained new navigation/help sections (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention label formatting was adjusted from 'Intervention / Treatment' to 'Intervention/Treatment'. Additionally, a 'No longer looking for participants' note was added and the revision version updated from v3.5.5 to v3.6.0.SummaryDifference0.5%

- Check65 days agoChange DetectedThe page's revision tag was updated from v3.5.4 to v3.5.5, indicating a minor backend/frontend update; no study data or enrollment details are changed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Poor-Prognosis CUP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Poor-Prognosis CUP Clinical Trial page.